Anticancer Drugs 2021

The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeut...

Full description

Saved in:
Bibliographic Details
Format: Online
Language:English
Published: MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
age
Trk
n/a
Online Access:ONIX_20220621_9783036543482_3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1869528307082461184
collection Directory of Open Access Books
description The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure–activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered.
format Online
id doab-20.500.12854ir-84569
institution Directory of Open Access Books
language eng
publishDate 2022
publishDateRange 2022
publishDateSort 2022
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-845692024-03-28T03:32:57Z Anticancer Drugs 2021 Meegan, Mary J O’Boyle, Niamh M thymidylate synthase cytotoxicity 1,2,3-triazole 1,3,4-oxadiazole 5-fluoruracil pemetrexed docking 3,4′-bis-guanidino 3-amino-4′-guanidino diphenyl ether phenyl pyridyl ether intramolecular hydrogen bond cancer cell viability HL-60 BRAF apoptosis thieno[2,3-d][1,2,3]triazine acetamide H1299 HER2 EGFR Bcl-2 inhibitors Indole-based analogues benzimidazole MTT cytotoxic assay cell cycle analysis DNA fragmentation ELISA solid/lipid nanoparticles phenstatin letrozole tubulin polymerisation inhibitor aromatase inhibitor breast cancer hybrid molecule dual-targeting molecule designed multiple ligand NaMSA cyclophosphamide histopathology testis urinary bladder anticancer agents enantioselective synthesis gastric adenocarcinoma tryptophanol concentration-guided dosing model informed dosing physiologically based pharmacokinetics sorafenib tyrosil-DNA-phosphodiesterase 1 adamantane resin acid TDP1 cytotoxic agents apoptosis induction HT-29 cells MDA-MB-231 cells mechanism prediction STAT inhibitors miR-21 hydrazide derivatives nitrogen scaffolds mitoxantrone cardiotoxicity inflammation oxidative stress age cumulative dose Trk NTRK tissue-agnostic larotrectinib entrectinib Trk fusion protein kinase inhibitors USFDA cancer patent review generic product doxazosin MD simulations combretastatin A-4 cytotoxic activity hybrid compounds indazole mucin MUC1 MUC16 immunotherapy cancer vaccine CAR (chimeric antigen receptor) ADC (antibody-drug conjugate) thiourea interleukin-6 trypan blue assay chalcones exportin-1 covalent binding CovDock anticancer activity xanthone in vitro in vivo isolation synthesis heterocyclic compound benzenesulfonamides imidazoles alkylated colony formation tumor spheroids HDAC inhibitors chalcone dual inhibitors carvedilol kidney toxicity 7-deaza-4′-thioadenosine derivatives multi-kinase inhibitor anticancer nucleoside Imiquimod drug efflux multidrug resistance Toll-Like Receptor n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PN Chemistry The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure–activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered. 2022-06-21T09:06:15Z 2022-06-21T09:06:15Z 2022 book ONIX_20220621_9783036543482_3 9783036543482 9783036543475 https://directory.doabooks.org/handle/20.500.12854/84569 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/5551 https://mdpi.com/books/pdfview/book/5551 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-4347-5 10.3390/books978-3-0365-4347-5 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036543482 9783036543475 594 Basel open access
spellingShingle thymidylate synthase
cytotoxicity
1,2,3-triazole
1,3,4-oxadiazole
5-fluoruracil
pemetrexed
docking
3,4′-bis-guanidino
3-amino-4′-guanidino
diphenyl ether
phenyl pyridyl ether
intramolecular hydrogen bond
cancer cell viability
HL-60
BRAF
apoptosis
thieno[2,3-d][1,2,3]triazine
acetamide
H1299
HER2
EGFR
Bcl-2 inhibitors
Indole-based analogues
benzimidazole
MTT cytotoxic assay
cell cycle analysis
DNA fragmentation
ELISA
solid/lipid nanoparticles
phenstatin
letrozole
tubulin polymerisation inhibitor
aromatase inhibitor
breast cancer
hybrid molecule
dual-targeting molecule
designed multiple ligand
NaMSA
cyclophosphamide
histopathology
testis
urinary bladder
anticancer agents
enantioselective synthesis
gastric adenocarcinoma
tryptophanol
concentration-guided dosing
model informed dosing
physiologically based pharmacokinetics
sorafenib
tyrosil-DNA-phosphodiesterase 1
adamantane
resin acid
TDP1
cytotoxic agents
apoptosis induction
HT-29 cells
MDA-MB-231 cells
mechanism prediction
STAT inhibitors
miR-21
hydrazide derivatives
nitrogen scaffolds
mitoxantrone
cardiotoxicity
inflammation
oxidative stress
age
cumulative dose
Trk
NTRK
tissue-agnostic
larotrectinib
entrectinib
Trk fusion
protein kinase inhibitors
USFDA
cancer
patent review
generic product
doxazosin
MD simulations
combretastatin A-4
cytotoxic activity
hybrid compounds
indazole
mucin
MUC1
MUC16
immunotherapy
cancer vaccine
CAR (chimeric antigen receptor)
ADC (antibody-drug conjugate)
thiourea
interleukin-6
trypan blue assay
chalcones
exportin-1
covalent binding
CovDock
anticancer activity
xanthone
in vitro
in vivo
isolation
synthesis
heterocyclic compound
benzenesulfonamides
imidazoles
alkylated
colony formation
tumor spheroids
HDAC inhibitors
chalcone
dual inhibitors
carvedilol
kidney
toxicity
7-deaza-4′-thioadenosine derivatives
multi-kinase inhibitor
anticancer
nucleoside
Imiquimod
drug efflux
multidrug resistance
Toll-Like Receptor
n/a
thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general
thema EDItEUR::P Mathematics and Science::PN Chemistry
Anticancer Drugs 2021
title Anticancer Drugs 2021
title_full Anticancer Drugs 2021
title_fullStr Anticancer Drugs 2021
title_full_unstemmed Anticancer Drugs 2021
title_short Anticancer Drugs 2021
title_sort anticancer drugs 2021
topic thymidylate synthase
cytotoxicity
1,2,3-triazole
1,3,4-oxadiazole
5-fluoruracil
pemetrexed
docking
3,4′-bis-guanidino
3-amino-4′-guanidino
diphenyl ether
phenyl pyridyl ether
intramolecular hydrogen bond
cancer cell viability
HL-60
BRAF
apoptosis
thieno[2,3-d][1,2,3]triazine
acetamide
H1299
HER2
EGFR
Bcl-2 inhibitors
Indole-based analogues
benzimidazole
MTT cytotoxic assay
cell cycle analysis
DNA fragmentation
ELISA
solid/lipid nanoparticles
phenstatin
letrozole
tubulin polymerisation inhibitor
aromatase inhibitor
breast cancer
hybrid molecule
dual-targeting molecule
designed multiple ligand
NaMSA
cyclophosphamide
histopathology
testis
urinary bladder
anticancer agents
enantioselective synthesis
gastric adenocarcinoma
tryptophanol
concentration-guided dosing
model informed dosing
physiologically based pharmacokinetics
sorafenib
tyrosil-DNA-phosphodiesterase 1
adamantane
resin acid
TDP1
cytotoxic agents
apoptosis induction
HT-29 cells
MDA-MB-231 cells
mechanism prediction
STAT inhibitors
miR-21
hydrazide derivatives
nitrogen scaffolds
mitoxantrone
cardiotoxicity
inflammation
oxidative stress
age
cumulative dose
Trk
NTRK
tissue-agnostic
larotrectinib
entrectinib
Trk fusion
protein kinase inhibitors
USFDA
cancer
patent review
generic product
doxazosin
MD simulations
combretastatin A-4
cytotoxic activity
hybrid compounds
indazole
mucin
MUC1
MUC16
immunotherapy
cancer vaccine
CAR (chimeric antigen receptor)
ADC (antibody-drug conjugate)
thiourea
interleukin-6
trypan blue assay
chalcones
exportin-1
covalent binding
CovDock
anticancer activity
xanthone
in vitro
in vivo
isolation
synthesis
heterocyclic compound
benzenesulfonamides
imidazoles
alkylated
colony formation
tumor spheroids
HDAC inhibitors
chalcone
dual inhibitors
carvedilol
kidney
toxicity
7-deaza-4′-thioadenosine derivatives
multi-kinase inhibitor
anticancer
nucleoside
Imiquimod
drug efflux
multidrug resistance
Toll-Like Receptor
n/a
thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general
thema EDItEUR::P Mathematics and Science::PN Chemistry
topic_facet thymidylate synthase
cytotoxicity
1,2,3-triazole
1,3,4-oxadiazole
5-fluoruracil
pemetrexed
docking
3,4′-bis-guanidino
3-amino-4′-guanidino
diphenyl ether
phenyl pyridyl ether
intramolecular hydrogen bond
cancer cell viability
HL-60
BRAF
apoptosis
thieno[2,3-d][1,2,3]triazine
acetamide
H1299
HER2
EGFR
Bcl-2 inhibitors
Indole-based analogues
benzimidazole
MTT cytotoxic assay
cell cycle analysis
DNA fragmentation
ELISA
solid/lipid nanoparticles
phenstatin
letrozole
tubulin polymerisation inhibitor
aromatase inhibitor
breast cancer
hybrid molecule
dual-targeting molecule
designed multiple ligand
NaMSA
cyclophosphamide
histopathology
testis
urinary bladder
anticancer agents
enantioselective synthesis
gastric adenocarcinoma
tryptophanol
concentration-guided dosing
model informed dosing
physiologically based pharmacokinetics
sorafenib
tyrosil-DNA-phosphodiesterase 1
adamantane
resin acid
TDP1
cytotoxic agents
apoptosis induction
HT-29 cells
MDA-MB-231 cells
mechanism prediction
STAT inhibitors
miR-21
hydrazide derivatives
nitrogen scaffolds
mitoxantrone
cardiotoxicity
inflammation
oxidative stress
age
cumulative dose
Trk
NTRK
tissue-agnostic
larotrectinib
entrectinib
Trk fusion
protein kinase inhibitors
USFDA
cancer
patent review
generic product
doxazosin
MD simulations
combretastatin A-4
cytotoxic activity
hybrid compounds
indazole
mucin
MUC1
MUC16
immunotherapy
cancer vaccine
CAR (chimeric antigen receptor)
ADC (antibody-drug conjugate)
thiourea
interleukin-6
trypan blue assay
chalcones
exportin-1
covalent binding
CovDock
anticancer activity
xanthone
in vitro
in vivo
isolation
synthesis
heterocyclic compound
benzenesulfonamides
imidazoles
alkylated
colony formation
tumor spheroids
HDAC inhibitors
chalcone
dual inhibitors
carvedilol
kidney
toxicity
7-deaza-4′-thioadenosine derivatives
multi-kinase inhibitor
anticancer
nucleoside
Imiquimod
drug efflux
multidrug resistance
Toll-Like Receptor
n/a
thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general
thema EDItEUR::P Mathematics and Science::PN Chemistry
url ONIX_20220621_9783036543482_3